Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes?

Biol Blood Marrow Transplant. 2014 Oct;20(10):1461-2. doi: 10.1016/j.bbmt.2014.07.026. Epub 2014 Jul 29.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Gene Expression
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunoglobulins / genetics
  • Immunotoxins / therapeutic use*
  • Neoplasm, Residual
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Prognosis
  • Recurrence
  • Risk Factors
  • Survival Analysis
  • Transplantation Chimera / genetics
  • Transplantation Chimera / immunology*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Immunoglobulins
  • Immunotoxins